Pomalidomide after CAR T for B-cell cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a type of B-cell cancer (leukemia or lymphoma) that has come back or not responded to treatment, and you have already received a CAR T-cell therapy approved for your cancer
- You are between 28 and 56 days after your CAR T-cell infusion when starting the study
- Your cancer is not growing or getting worse right now
- You do not have severe side effects from CAR T therapy, like uncontrolled inflammation or nerve problems
- You must be willing to join a long-term follow-up study for bone marrow transplant patients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
This study looks at using two drugs, pomalidomide and rituximab, as maintenance therapy after initial treatment for younger adults with a high-risk type of non-Hodgkin lymphoma called DLBCL. The goal is to see if this combination helps keep the cancer in remission longer.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a new type of CAR T-cell therapy that targets two proteins on cancer cells (CD20 and CD19) for B-cell cancers like lymphoma and leukemia that have come back or not responded to other treatments. It might help you if your cancer hasn't been controlled by standard options.
Hear when a new Recurrent B Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.